Readystate Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Readystate Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.69M	Buy	+144,238	New	+$2.39M	0.12%	118

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Readystate Asset Management's MLTX Position: Q1 2026 in Review

Readystate Asset Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q1 2026: 144,238 shares worth $2.69M. The stake represents 0.12% of the portfolio and ranks #118 among its holdings.

147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Readystate Asset Management held 144,238 shares of MoonLake Immunotherapeutics worth $2.69M as of Q1 2026.
MoonLake Immunotherapeutics was a new Readystate Asset Management position in Q1 2026.
MoonLake Immunotherapeutics made up 0.12% of Readystate Asset Management's portfolio in Q1 2026, its #118 holding.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.